Rikke

About PlusR

This author has not yet filled in any details.
So far PlusR has created 990 blog entries.

News from South Eastern Europe

2024-07-10T11:10:18+02:00July 10, 2024|Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Europe, Greece, HAEi News, Kosovo, Montenegro, North Macedonia, Romania, Serbia, Slovenia, Turkey|

From Regional Patient Advocate Natasa Angjeleska In this edition of Global Perspectives, I’m delighted to bring you a detailed report on the SEE HAE Meeting: PROVIDING BETTER CARE FOR HAE FAMILIES held in Skopje, North Macedonia, from 31 May to 1 June. It took us a couple of months to secure funding and implement [...]

HAEi Regional Patient Advocates – Many Faces One Family!

2024-07-10T10:18:38+02:00July 10, 2024|HAEi News|

I vividly remember attending the HAEi Global Conference in Copenhagen in May of 2012, when the hae day :-) and its theme, “Many Faces One Family” were introduced. Many of us met in person in Denmark for the first time and have followed HAEi’s path since. We arrived in Copenhagen from all over the [...]

KalVista initiates KONFIDENT-KID trial for on-demand treatment of HAE attacks with sebetralstat in children aged 2 to 11

2024-06-30T08:41:48+02:00June 27, 2024|HAEi News|

KalVista initiates KONFIDENT-KID trial for on-demand treatment of hereditary angioedema attacks with sebetralstat in children aged 2 to 11 KalVista Pharmaceuticals, Inc, today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged 2 to 11 years across [...]

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for HAE

2024-06-19T12:04:53+02:00June 18, 2024|HAEi News|

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals, Inc, today announced the submission of a New Drug Application (NDA) for US Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema [...]

KalVista Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

2024-06-10T11:19:13+02:00June 6, 2024|HAEi News|

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 KalVista Pharmaceuticals announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT [...]

Pharvaris highlights properties of deucrictibant in data presentations at recent congresses

2024-06-06T11:17:20+02:00June 4, 2024|HAEi News|

Pharvaris highlights properties of deucrictibant in data presentations at recent congresses Pharvaris recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European [...]

KalVista presents data on persisting unmet needs in HAE at the EAACI Congress 2024

2024-06-06T11:15:28+02:00June 3, 2024|HAEi News|

KalVista Pharmaceuticals presents data on persisting unmet needs in hereditary angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 KalVista Pharmaceuticals announced that it presented real-world data from patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology [...]

BioCryst presents new real-world evidence showing reductions in attack rates in HAE patients with mormal C1-inhibitor after beginning Orladeyo (berotralstat) treatment

2024-06-06T11:13:57+02:00June 2, 2024|HAEi News|

BioCryst presents new real-world evidence showing reductions in attack rates in HAE patients with mormal C1-inhibitor after beginning Orladeyo (berotralstat) treatment Biocryst Pharmaceuticals Inc announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily [...]

Intellia announces positive long-term data from ongoing phase 1 study of NTLA-2002

2024-06-06T11:12:42+02:00June 2, 2024|HAEi News|

Intellia Therapeutics announces positive long-term data from ongoing phase 1 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema Intellia Therapeutics announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development [...]

Go to Top